HeioThera

HeioThera is a Chicago-based biotechnology company focused on developing next-generation immunotherapies for autoimmune and inflammatory diseases. The company utilizes a proprietary protein engineering platform to create cytokines that specifically target lymph nodes by leveraging interactions with the neonatal Fc receptor (FcRn). This localized delivery is designed to induce sustained immunological tolerance and "calm" the autoimmune response without the systemic side effects associated with traditional immunosuppressants. HeioThera's pipeline targets a broad range of conditions, including multiple sclerosis, rheumatoid arthritis, and scleroderma.